Sir, my question is regarding the U.S. So, have you done any filings in this quarter? What is the number of YTD -- filings YTD?
Okay. And, sir, any launches this quarter?
Questions across 4 calls
Amlan Das
Nomura India
Alkem Laboratories Limited
Ajanta Pharma Limited
Hi, sir. I just wanted to ask what is your outlook for the Africa antimalarial business? Is it going to remain low? Or do you have any outlook regarding this?
Okay sir, thank you. Sir, one more question regarding the India business. Have you booked any sales for the new therapies that you have added in this quarter? There is the 12% growth? What is the contribution of this new therapies?
Neuland Laboratories Limited
My question is regarding the CMS business. So , since the last 6 to 8 quarters, it has been contributing around 49% to 55% of total revenues. Since you are saying that the order book has been going strong and you are expecting a high growth in FY26, can we expect this share to go up beyond the 55% mark? And how do you see the CMS business going forward? So , the peak revenue -- quarterly revenues have been around INR230 crores in Q1FY25. So what is the outlook regarding this business in FY26?
I was actually trying to understand the margin profile since the CMS business is a high-margin business for you. So, what do you see as the stable EBITDA margin going forward? Would it be stable at around current levels of 27%, 28% that you are making? Or we expect it to go up?
Mankind Pharma Limited
Sir, my question is regarding the regulatory restrictions that you have written for the acute products. Could you please elaborate on that a bit?
Okay. Sir, one more question on the Dydrogesterone project, what is the update there? How is the progress in the last quarter?